| 6th Jun 2023 10:00 am |
RNS |
LTIP and Share Option Scheme |
| 31st May 2023 9:30 am |
RNS |
Total Voting Rights |
| 26th May 2023 7:00 am |
RNS |
Fruquintinib NDA Granted Priority Review by FDA |
| 26th May 2023 7:00 am |
RNS |
HUTCHMED Highlights Presentations at ASCO 2023 |
| 17th May 2023 9:30 am |
RNS |
Standard form for notification of major holdings |
| 12th May 2023 1:15 pm |
RNS |
Annual General Meeting Poll Results |
| 12th May 2023 9:30 am |
RNS |
Board of Directors and Board Committee Membership |
| 10th May 2023 9:30 am |
RNS |
Appointment of Independent NED |
| 28th Apr 2023 9:30 am |
RNS |
Total Voting Rights |
| 21st Apr 2023 9:30 am |
RNS |
Vesting of awards under the LTIP |
| 18th Apr 2023 7:00 am |
RNS |
NDA Acceptance in China for Fruquintinib |
| 12th Apr 2023 7:00 am |
RNS |
Presentations at AACR Annual Meeting 2023 |
| 11th Apr 2023 9:30 am |
RNS |
Intended Retirement of Independent NED |
| 11th Apr 2023 9:30 am |
RNS |
2022 Annual Report and Notice of AGM |
| 4th Apr 2023 10:30 am |
RNS |
HUTCHMED Initiates Registration Phase Enrollments |
| 31st Mar 2023 9:30 am |
RNS |
Total Voting Rights |
| 31st Mar 2023 7:00 am |
RNS |
Rolling Submission of Fruquintinib US NDA Complete |
| 14th Mar 2023 1:30 pm |
RNS |
Closing of Fruquintinib License to Takeda |
| 8th Mar 2023 8:30 am |
RNS |
Director's Share Dealing |
| 6th Mar 2023 8:30 am |
RNS |
Vesting of awards under the LTIP |
| 28th Feb 2023 12:15 pm |
RNS |
Publication of Form 20-F |
| 28th Feb 2023 8:30 am |
RNS |
2022 Full Year Results and Business Updates |
| 27th Feb 2023 10:00 am |
RNS |
Enrollment Completed in Phase 2 Amdizalisib trial |
| 31st Jan 2023 8:30 am |
RNS |
Notice of Results |
| 23rd Jan 2023 8:00 am |
RNS |
License to Takeda for Fruquintinib outside China |
| 18th Jan 2023 2:30 pm |
RNS |
Inclusion of ORPATHYS in NRDL in China |
| 3rd Jan 2023 8:30 am |
RNS |
Enrollment Completed in Phase 3 Trial |
| 30th Dec 2022 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 19th Dec 2022 10:00 am |
RNS |
FDA NDA Rolling Submission for Fruquintinib |
| 15th Nov 2022 7:00 am |
RNS |
HUTCHMED Announces Strategy Update |
| 14th Nov 2022 7:00 am |
RNS |
Positive Topline Phase 3 Result in Fruquintinib |
| 27th Oct 2022 12:30 pm |
RNS |
HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib |
| 21st Oct 2022 9:30 am |
RNS |
Vesting of awards under the LTIP |
| 10th Oct 2022 9:30 am |
RNS |
Phase II/III Trial of Sovleplenib for in China |
| 30th Sep 2022 9:30 am |
RNS |
Total Voting Rights |
| 14th Sep 2022 11:00 am |
RNS |
Share Option Scheme and Long Term Incentive Plan |
| 8th Sep 2022 7:00 am |
RNS |
FRESCO-2 Colorectal Cancer MRCT Data Highlights |
| 23rd Aug 2022 10:00 am |
RNS |
Holding(s) in Company |
| 23rd Aug 2022 9:30 am |
RNS |
HUTCHMED To Present FRESCO-2 Data at ESMO 2022 |
| 9th Aug 2022 9:30 am |
RNS |
First Participant in Phase I Trial of IMG-004 |
